[Follow-up study on anti-HBs levels in vaccinees after two and three doses of HB vaccine. (2)].
An HB prophylaxis vaccination that included a primary and secondary vaccination was carried out on persons working at the university hospital. In the primary vaccination group, the subjects were inoculated the second time with a vaccine derived from human blood plasma obtained from the Kitazato Therapeutic Research Institute. The third time, they were inoculated with a vaccine from the Chemo-Sero Therapeutic Research Institute derived from a second-generation vaccine organized ferment. The vaccine used for the second inoculation group was obtained from the Chemo-Sero Therapeutic Research Institute. Results were summarized as follows: 1) The primary vaccination group: (1) The number of the 153 subjects inoculated with the primary vaccination at the time of the second inoculation, 49 subjects (32%) tested positive for antibodies 3-4 months following inoculation. Thirty-two subjects (20%) tested positive 15-16 months following inoculation with a high rate among females. (2) Among 104 subjects inoculated the third time with the primary vaccination (those who tested negative the second inoculation of the above vaccine), 61 subjects (58.7%) tested positive for antibodies 8-9 months following inoculation with a generally high rate among females. Twenty-eight subjects (26%) tested 15-16 months after inoculation with a high rate among females between 20 and 30 years and among males between 40 and years. 2) The secondary group: Among the 38 subjects who were inoculated the second time with the secondary vaccination, 8 subjects (21%) tested positive for antibodies 5-6 months following inoculation, with a high rate among females in their 20's. 3) The rate of antibodies formation.(ABSTRACT TRUNCATED AT 250 WORDS)
Kimura
T
T
Department of Clinical Pathology and Clinical Laboratories, Kanagawa Dental College.
Iwamiya
M
M
Yoshida
N
N
Iwamoto
A
A
Sasada
M
M
Ito
S
S
Kikuchi
N
N
Kimoto
S
S
D000328:Adult; D000367:Age Factors; D000917:Antibody Formation; D005260:Female; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D012737:Sex Factors; D014611:Vaccination; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D014761:Viral Hepatitis Vaccines